Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Compliance 360° Part 11: Turn Your CMO Nightmare Into A Dream Come True (2 of 2)

Executive Summary

This is Compliance 360°, a podcast series from Medtech Insight on US FDA compliance and enforcement issues. In this 11th installment – the second of two parts – former FDA investigations branch director Ricki Chase discusses some of the more complex problems that may arise in the relationship between the owners of regulated products and contract manufacturing organizations (CMOs), and how to solve them.

The relationship between the owners of regulated products and contract manufacturing organizations can be made unnecessarily complex when the owners make changes to medical devices without first notifying their CMOs.

"This can happen with product design changes, material changes and/or supplier changes," former US FDA investigations branch director Ricki Chase says. That's why "design changes should be discussed with the CMO before they are made. A design change may involve the need for new tooling or a need for the process to undergo validation after the design change; it may also involve the need for new or different testing to be performed."

In this 11th installment of Compliance 360°, a podcast series from Medtech Insight on FDA compliance and enforcement issues, Chase points out that owners also need to alert CMOs if there are changes to components or raw materials.

"A change in raw materials or the supplier of the raw material can have a direct impact on how the material reacts in the manufacturing process. Further, changes in materials can cause new and unexpected problems with the manufacturer’s equipment. The CMO should know about these changes before they take place," she says.

Chase is compliance practice director for Lachman Consultant Services, a firm she joined in 2016 after spending 16 years at FDA, where she was also an investigator, medical device specialist and supervisory investigator.

Listen to the second part of this CMO podcast via the player below…

…And, if you missed it, check out part one below:

 

 

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT121695

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel